Literature DB >> 15476669

2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.

Zhan-Guo Gao1, Liaman K Mamedova, Peiran Chen, Kenneth A Jacobson.   

Abstract

The affinity and efficacy at four subtypes (A(1), A(2A), A(2B) and A(3)) of human adenosine receptors (ARs) of a wide range of 2-substituted adenosine derivatives were evaluated using radioligand binding assays and a cyclic AMP functional assay in intact CHO cells stably expressing these receptors. Similar to previous studies of the N(6)-position, several 2-substituents were found to be critical structural determinants for the A(3)AR activation. The following adenosine 2-ethers were moderately potent partial agonists (K(i), nM): benzyl (117), 3-chlorobenzyl (72), 2-(3-chlorophenyl)ethyl (41), and 2-(2-naphthyl)ethyl (130). The following adenosine 2-ethers were A(3)AR antagonists: 2,2-diphenylethyl, 2-(2-norbornan)ethyl, R- and S-2-phenylbutyl, and 2-(2-chlorophenyl)ethyl. 2-(S-2-Phenylbutyloxy)adenosine as an A(3)AR antagonist right-shifted the concentration-response curve for the inhibition by NECA of cyclic AMP accumulation with a K(B) value of 212 nM, which is similar to its binding affinity (K(i) = 175 nM). These 2-substituted adenosine derivatives were generally less potent at the A(1)AR in comparison to the A(3)AR, but fully efficacious, with binding K(i) values over 100 nM. The 2-phenylethyl moiety resulted in higher A(3)AR affinity (K(i) in nM) when linked to the 2-position of adenosine through an ether group (54), than when linked through an amine (310) or thioether (1960). 2-[2-(l-Naphthyl)ethyloxy]adenosine (K(i) = 3.8 nM) was found to be the most potent and selective (>50-fold) A(2A) agonist in this series. Mixed A(2A)/A(3)AR agonists have been identified. Interestingly, although most of these compounds were extremely weak at the A(2B)AR, 2-[2-(2-naphthyl)ethyloxy]adenosine (EC(50) = 1.4 microM) and 2-[2-(2-thienyl)-ethyloxy]adenosine (EC(50) = 1.8 microM) were found to be relatively potent A(2B) agonists, although less potent than NECA (EC(50) = 140 nM).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476669      PMCID: PMC3408601          DOI: 10.1016/j.bcp.2004.06.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  37 in total

1.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.

Authors:  A Ohta; M Sitkovsky
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

2.  5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors.

Authors:  E W van Tilburg; P A van der Klein; J von Frijtag Drabbe Künzel; M de Groote; C Stannek; A Lorenzen; A P IJzerman
Journal:  J Med Chem       Date:  2001-08-30       Impact factor: 7.446

3.  Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.

Authors:  Susanna Tchilibon; Soo-Kyung Kim; Zhan-Guo Gao; Brian A Harris; Joshua B Blaustein; Ariel S Gross; Heng T Duong; Neli Melman; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2004-05-01       Impact factor: 3.641

4.  3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.

Authors:  Michael P DeNinno; Hiroko Masamune; Lois K Chenard; Kenneth J DiRico; Cynthia Eller; John B Etienne; Jeanene E Tickner; Scott P Kennedy; Delvin R Knight; Jimmy Kong; Joseph J Oleynek; W Ross Tracey; Roger J Hill
Journal:  J Med Chem       Date:  2003-01-30       Impact factor: 7.446

5.  An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Gil Ohana; Faina Barer; Avivit Ochaion; Abigail Erlanger; Lea Madi
Journal:  Oncogene       Date:  2004-04-01       Impact factor: 9.867

6.  Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.

Authors:  Soo-Kyung Kim; Zhan-Guo Gao; Philippe Van Rompaey; Ariel S Gross; Aishe Chen; Serge Van Calenbergh; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2003-11-06       Impact factor: 7.446

7.  A2B adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyl adenosine and NECA derivatives.

Authors:  S Vittori; S Costanzi; C Lambertucci; F R Portino; S Taffi; R Volpini; K N Klotz; G Cristalli
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2004       Impact factor: 1.381

Review 8.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

9.  N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.

Authors:  Zhan-Guo Gao; Joshua B Blaustein; Ariel S Gross; Neli Melman; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2003-05-15       Impact factor: 5.858

Review 10.  Partial agonists for A(3) adenosine receptors.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

View more
  32 in total

1.  Purine receptors: GPCR structure and agonist design.

Authors:  Kenneth A Jacobson; Soo-Kyung Kim; Stefano Costanzi; Zhan-Guo Gao
Journal:  Mol Interv       Date:  2004-12

2.  Nucleoside modification and concerted mutagenesis of the human A3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop.

Authors:  Heng T Duong; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2005       Impact factor: 1.381

3.  Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.

Authors:  Shantanu Pal; Won Jun Choi; Seung Ah Choe; Cara L Heller; Zhan-Guo Gao; Moshe Chinn; Kenneth A Jacobson; Xiyan Hou; Sang Kook Lee; Hea Ok Kim; Lak Shin Jeong
Journal:  Bioorg Med Chem       Date:  2009-03-25       Impact factor: 3.641

4.  Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor.

Authors:  Zhan-Guo Gao; Ramachandran Balasubramanian; Evgeny Kiselev; Qiang Wei; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2014-05-20       Impact factor: 5.858

Review 5.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-adrenergic receptor and the human adenosine A2A receptor.

Authors:  Farag F Sherbiny; Anke C Schiedel; Astrid Maass; Christa E Müller
Journal:  J Comput Aided Mol Des       Date:  2009-11       Impact factor: 3.686

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 8.  Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Soo-Kyung Kim; Eunjoo Roh; Bhalchandra V Joshi; Susanna Tchilibon; Heng T Duong; Zhan-Guo Gao
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2006       Impact factor: 1.381

9.  Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.

Authors:  Lak Shin Jeong; Shantanu Pal; Seung Ah Choe; Won Jun Choi; Kenneth A Jacobson; Zhan-Guo Gao; Athena M Klutz; Xiyan Hou; Hea Ok Kim; Hyuk Woo Lee; Sang Kook Lee; Dilip K Tosh; Hyung Ryong Moon
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

10.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.